Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

in royalty revenues was in line with our expectations and results from a decline in sales of Thalomid® in the United States.  We will continue to carefully monitor and control expenses and deploy capital in strategic ways."  Further up-to-date information regarding the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, can be found on our web site at www.entremed.com.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expect
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Telbec/ - Mirego, leader in mobile strategies and solutions, is ... app extensions for the all new Apple Watch. Made in ... and MediaMiser, these extensions will reinvent the way users receive ... wrist use.  Available today in ... tactile smartwatch that makes for an excellent buddy for business, ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... Mount Dora, Florida (PRWEB) April 23, 2015 ... announced that it intends to conduct a groundbreaking ... can begin to be reversed in as little ... researchers—using the science of metabolic and nutritional medicine—will ... conditions that cripple and destroy our aging brain. ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
Breaking Biology Technology:Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... 20 Humanitarian, Dr. Gary Michelson,is "making an ... Gilbreath, Executive Director of Found Animals Foundation (Found,Animals) ... Found Animals and its strategic partner the Alliance ... launch of The Michelson Prize in,Reproductive Biology at ...
... The Board of Directors,of Eli Lilly and Company ... as a,new member, effective December 1, 2008. Oberhelman, 55, ... is a member of Caterpillar,s,executive office. As a member ... audit committee and finance committee. He will stand for,election ...
... ORANGE COUNTY, Calif., Oct. 20 Beckman,Coulter, Inc. ... Board of Directors,declared a quarterly dividend payout of ... payable on November 17, 2008 to all,stockholders of ... the 78th,consecutive, quarterly payout of dividends., (Logo: ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... found that pre-existing malaria prevents secondary infection by another ... iron availability in the liver of the host. This ... Nature Medicine and has important implications for ... affects millions of individuals worldwide. The study was ...
... a class of compounds that could be a boon to ... study, published online in Nature Chemical Biology on ... and selectively block the activity of a large and diverse ... hydrolase-blocking compounds have been turned into drugs to treat obesity, ...
... May 15, 2011) An international research team ... Institute for Breast Cancer Research at Princess Margaret Hospital ... the process whereby tumour cells adapt and survive under ... published today in Genes and Development ( ...
Cached Biology News:Malaria against malaria: A pre-existing malaria infection can prevent a second infection 2Malaria against malaria: A pre-existing malaria infection can prevent a second infection 3Scientists find new class of compounds with great potential for research and drug development 2Scientists find new class of compounds with great potential for research and drug development 3Cancer scientists discover new way breast cancer cells adapt to environmental stress 2
...
Chicken anti-EEA1...
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Biology Products: